Physician profile
Ari L Bunim
NPI 1386707933
$296,673.95
in general payments reported to CMS, 2019-2025
30 companies · $89K in 2025
The $89K reported for 2025 was more than what 99% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $77K · 2020: $16K · 2021: $19K · 2022: $25K · 2023: $21K · 2024: $49K · 2025: $89K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $134K · Travel and Lodging: $11K · Food and Beverage: $8,982 · Consulting Fee: $4,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $134,133.81 |
| Travel and Lodging | $11,215.84 |
| Food and Beverage | $8,981.93 |
| Consulting Fee | $4,785.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $96,529.06 | 2024-2025 | Rezdiffra, Resmetirom |
| Gilead Sciences, INC. | $82,155.20 | 2019-2025 | Epclusa |
| Abbvie INC. | $75,982.92 | 2019-2025 | Mavyret, Skyrizi, Rinvoq |
| Novo Nordisk INC | $15,998.29 | 2025 | Wegovy, Saxenda |
| Intercept Pharmaceuticals, INC. | $15,035.80 | 2019-2025 | Ocaliva |
| Takeda Pharmaceuticals U.S.A., INC. | $4,184.98 | 2019-2025 | Entyvio |
| Dova Pharmaceuticals | $3,224.91 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,522.60 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Ardelyx, INC. | $303.43 | 2022-2025 | Ibsrela |
| Echosens North America, INC. | $260.50 | 2019 | |
| Celgene Corporation | $248.59 | 2021-2024 | Zeposia |
| Qol Medical, LLC | $234.19 | 2022-2025 | Sucraid |
| Phathom Pharmaceuticals, INC. | $207.56 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $149.15 | 2019-2025 | Simponi Aria, Stelara, Simponi |
| Aimmune Therapeutics, INC. | $142.59 | 2024-2025 | Vowst |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $74.34 | 2019 | |
| Merck Sharp & Dohme LLC | $69.67 | 2019-2023 | Dificid |
| Braintree Laboratories, INC. | $54.40 | 2025 | Suflave, Sutab |
| Ironwood Pharmaceuticals, INC | $42.90 | 2023-2024 | Linzess |
| Lilly USA, LLC | $40.94 | 2025 | Omvoh |
| Orphalan INC | $28.21 | 2024 | Cuvrior |
| Ipsen Biopharmaceuticals, INC | $28.11 | 2025 | Iqirvo |
| Amgen INC. | $23.49 | 2025 | Uplizna |
| Mallinckrodt Hospital Products INC. | $22.50 | 2022 | |
| W. L. Gore & Associates, INC. | $22.14 | 2023 | Gore Cardioform Septal Occluder |
| Nestle Healthcare Nutrition INC. | $21.62 | 2023 | |
| Daiichi Sankyo INC. | $19.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $18.22 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $15.18 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $13.39 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Bunim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.